Gå offline med appen Player FM !
ESMO, WCLC lung cancer data spark hope—and debate
Manage episode 442294803 series 3386301
At the recent World Conference on Lung Cancer and European Society for Medical Oncology annual meetings, two packages of lung cancer data from a partnership between Akeso and Summit Therapeutics and another collaboration between iTeos Therapeutics and GSK showed much promise of disrupting the current standard of care. But they also drew some questions and debate.
In this week's episode of “The Top Line,” Angus Liu from Fierce Pharma and Gabrielle Masson from Fierce Biotech discuss the key issues behind those two readouts.
To learn more about the topic in this episode:
- iTeos-GSK's TIGIT combo shows 30% more tumor shrinkage than Jemperli, but safety signals scare investors
- Akeso, Summit's PD-1 bispecific crushes Merck's Keytruda in study, signaling potential new standard in lung cancer
- 'Cooking with gas': Regeneron sees its Opdualag rival as next big thing for treating solid tumors
- ESMO: Bristol Myers moves Opdualag into phase 3 trials in competitive first-line lung cancer field
See omnystudio.com/listener for privacy information.
100 episoder
Manage episode 442294803 series 3386301
At the recent World Conference on Lung Cancer and European Society for Medical Oncology annual meetings, two packages of lung cancer data from a partnership between Akeso and Summit Therapeutics and another collaboration between iTeos Therapeutics and GSK showed much promise of disrupting the current standard of care. But they also drew some questions and debate.
In this week's episode of “The Top Line,” Angus Liu from Fierce Pharma and Gabrielle Masson from Fierce Biotech discuss the key issues behind those two readouts.
To learn more about the topic in this episode:
- iTeos-GSK's TIGIT combo shows 30% more tumor shrinkage than Jemperli, but safety signals scare investors
- Akeso, Summit's PD-1 bispecific crushes Merck's Keytruda in study, signaling potential new standard in lung cancer
- 'Cooking with gas': Regeneron sees its Opdualag rival as next big thing for treating solid tumors
- ESMO: Bristol Myers moves Opdualag into phase 3 trials in competitive first-line lung cancer field
See omnystudio.com/listener for privacy information.
100 episoder
Alla avsnitt
×Välkommen till Player FM
Player FM scannar webben för högkvalitativa podcasts för dig att njuta av nu direkt. Den är den bästa podcast-appen och den fungerar med Android, Iphone och webben. Bli medlem för att synka prenumerationer mellan enheter.